Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy
September 09 2019 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International Reports NanoStilbene™ Protects the Immune
System
from Cancer Chemotherapy
Newly Discovered Properties of
NanoStilbene Potentially Allows Company to Address
$3.9 Billion Chemotherapy Induced Neutropenia
Market
OCEANSIDE, CA --
September 9, 2019 -- InvestorsHub NewsWire
-- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
today new data and
the
filing of
a patent application covering the ability of NanoStilbene™
[1]
and its
active ingredient, pterostilbene, at accelerating recovery of blood
cells after treatment with chemotherapy.
Neutropenia is
an abnormally low number of neutrophils (a type of white blood
cell) in the blood. Neutropenia,
if severe, significantly increases the risk of life-threatening
infection. Neutropenia is
often a side effect of the treatment of cancer with chemotherapy or
radiation therapy.
In animals treated
with the chemotherapeutic agent 5-fluorouracil,
recovery of white blood cells occurred significantly faster in
animals that also received NanoStilbene™ as compared to animals
that received a placebo. The
results were replicated with other types of chemotherapy including
high dose cyclophosphamide and busulfan.
"We have previously
reported that NanoStilbene™ can synergize with low dose
cyclophosphamide at increasing immune response and killing of
cancer [2]" said Dr. James
Veltmeyer, Chief Medical Officer of the Company.
"This
new data
supports the possibility of
using NanoStilbene™ in many cancer patients who are taking
chemotherapy, in order to protect the patients from the side
effects of chemotherapy. In many cases, patients receiving
chemotherapy have reduced white blood cells, which
causes various types of
infectious disease."
Currently, drugs such
as Neulasta™ and Neupogen™ are used for increasing white blood
cells in cancer patients taking chemotherapy. Unfortunately,
these drugs cannot be taken prophylactically, and are highly
expensive. According to Fierce Pharma, Neulasta™
had sales
of $3.8 billion in
2018 [3]. More
importantly, NanoStilbene possesses direct cancer-inhibitory
properties, meaning that potentially it not only prevents
chemotherapy-associated side effects but also increases the
activity of the chemotherapy to kill cancer.
"I am impressed by
the wide spectrum activity of the NanoStilbene™ product. It
is very rare to find a therapy that concurrently suppresses the
growth of cancer, stimulates the immune system, and
protects
the bone marrow from chemotherapy-induced toxicity"
said
Dr.
Feng Lin,
Chief Scientific Officer of the Company. "Since NanoStilbene™
is already on the market as a nutraceutical, I
anticipate it will rapidly be utilized by informed patients who are
suffering from cancer."
NanoStilbene is a
nanoemulsion of nanoparticle pterostilbene in the range of 75-100nm
at a concentration of 200mg per milliliter. Nanoparticle
therapeutics is an emerging treatment modality for cancer and other
inflammatory disorders. The National Cancer Institute has
recognized nanotechnology as an emerging field with the potential
to revolutionize modern medicine for the detection, treatment, and
prevention of cancer.
"This Company was
founded not only to advance great science but more importantly, to
help patients for which limited options exist. The
development of NanoStilbene™, we believe, offers the potential of a
new generation of non-toxic compounds
that
concurrently stimulate the immune system while suppressing
cancer at the same
time" said Timothy Dixon,
President, and CEO of the Company.
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
[1] https://mynanostilbene.com/?page_id=159
[2]
https://www.globenewswire.com/news-release/2019/07/29/1892915/0/en/NanoStilbene-Nutraceutical-Shown-to-Increase-Ability-of-Cyclophosphamide-Chemotherapy-to-Suppress-Cancer.html
[3]
https://www.fiercepharma.com/special-report/9-neulasta
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements
contained in this release are subject to certain risks and
uncertainties that could cause actual results to differ materially
from the statements made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024